An observational study in Pancreatic Cystic Lesion, Mucinous Cystadenoma of Pancreas and Intraductal Papillary Mucinous Neoplasm of Pancreas, sponsored by Huazhong University of Science and Technology. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by Huazhong University of Science and Technology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective is to construct a multimodal AI model (Cyst-AI) based on EUS images and clinical data such as imaging features(CT or MRI) and laboratory tests to assist endoscopists in the diagnosis of pancreatic cystic lesions(PCLs), mainly differentiating mucinous from non-mucinous lesions.
The secondary objective is to evaluate the model's effectiveness in risk stratification and clinical management for patients with PCLs.
With the development of medical imaging technology, the detection rate of pancreatic cystic lesions (PCLs) has been increasing notably. Although most cysts are benign, a considerable subset has the potential for malignant transformation. Clinical management is based on diagnosis and risk stratification. For PCLs,different diagnosis and risk stratification lead to entirely different clinical strategies and outcomes, which are closely related to the quality of life, economic burden, and psychological stress of patients. Endoscopic ultrasound (EUS) has played a crucial role in the further differential diagnosis of PCLs. Artificial intelligence (AI) has also shown great potential in clinical diagnosis and management. Thus, we plan to retrospectively collect patients' EUS imaging data, radiological and laboratory tests, and other clinical information to construct a model named Cyst-AI which integrates the function of diagnosis and clinical management, to assist in clinical decision-making.
32 studies on the registry are indexed under Pancreatic Intraductal Neoplasms; 21 are open to participants now.
This study's planned enrollment of 500 is below the median of 586 across 17 observational studies indexed under Pancreatic Intraductal Neoplasms.
Browse Pancreatic Intraductal Neoplasms studies →Huazhong University of Science and Technology is the lead sponsor of 248 studies on the registry; 62 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The cohort will be selected from several hospitals in China, including Tongji Hospital, Tongji Medical College, HUST.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients before 2026 with EUS pictures of pancreatic cystic lesions or cystoid-material lesions have been included in this cohort.
Diagnostic Test: Cyst-AI model
The multi-center collected data will be divided into a training set, a validation set, and a test set for developing and testing the cyst-AI model.
The performance of the diagnostic model in differentiating mucinous from non-mucinous PCLs
The performance of the Cyst-AI diagnostic model will be evaluated using the area under the receiver operating characteristic curve (AUC-ROC), with sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) calculated from the model's predictions on the independent validation dataset. PCLs: pancreatic cystic lesions.
Time frame: Within 3 months upon completion of the diagnostic model training.
The risk stratification performance of the clinical management model for mucinous PCLs
The performance of the Cyst-AI risk stratification model to correctly classify lesions into "low risk", "intermediate risk" and "high risk", will be evaluated using the area under the receiver operating characteristic curve (AUC-ROC), with sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) calculated from the model's predictions on the independent validation dataset. PCLs: pancreatic cystic lesions.
Time frame: Within 3 months upon completion of the risk stratification model training.
The performance of the diagnostic model in differentiating specific types of PCLs
The performance of the Cyst-AI diagnostic model will be evaluated using the area under the receiver operating characteristic curve (AUC-ROC), with sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) calculated from the model's predictions on the independent validation dataset. PCLs: pancreatic cystic lesions.
Time frame: Within 3 months upon completion of the diagnostic model training.
The clinical management performance of the clinical management model for mucinous PCLs
The performance of the Cyst-AI clinical management model to provide accurate clinical recommendations, will be evaluated using the area under the receiver operating characteristic curve (AUC-ROC), with sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) calculated from the model's predictions on the independent validation dataset. PCLs: pancreatic cystic lesions.
Time frame: Within 3 months upon completion of the clinical management model training.
The performance of the model in assisting endoscopists of different levels in diagnosing and managing PCLs
The performance of the Cyst-AI model in assisting endoscopists will be evaluated using the area under the receiver operating characteristic curve (AUC-ROC), with sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) calculated from the model's predictions on the independent validation dataset. PCLs: pancreatic cystic lesions.
Time frame: Within 1 months upon completion of the human-machine confrontational crossover study
The impact of the model on the decision-making process of endoscopists
Questionnaire for endoscopists after assessment will be used to evaluate the degree of impact.
Time frame: Within 1 months upon completion of the human-machine confrontational crossover study.
Started Jan 2025 (actual). Primary completion is estimated for Apr 2026, 15 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pancreatic Intraductal Neoplasms →
Huazhong University of Science and Technology →